Abobotulinum toxin A and onabotulinum toxin A for masseteric hypertrophy: a split-face study in 25 Korean patients
ABSTRACT Abstract Masseter muscle hypertrophy has been treated for cosmetic purposes using several modalities, including injection of type A or type B botulinum toxin into the masseter muscle. In this report, we compared the efficacy and safety of abobotulinum toxin A with onabotulinum toxin A treatment for masseteric hypertrophy in 25 Korean patients with a conversion factor of 2.5:1 through a controlled, split-face, and evaluator-blinded study. The mean grade of clinical improvement based on clinical assessment was 2.8 ± 0.9 for abobotulinum toxin A and 2.7 ± 0.8 for onabotulinum toxin A at 8 weeks after the injection. At 12 weeks after the injection, the mean grade of clinical improvement based on clinical assessment was 2.9 ± 0.9 for abobotulinum toxin A and 2.7 ± 0.8 for onabotulinum toxin A. More pronounced improvement was observed with abobotulinum toxin A than onabotulinum toxin A in three (12%) patients at 8 weeks and five (20%) patients at 12 weeks. We believe that our data can be used as an essential reference for determining the dose of type A botulinum toxin in the treatment of masseteric hypertrophy.
SourceAvailable from: Mathieu Zuber[Show abstract] [Hide abstract]
ABSTRACT: Botulinum toxin type A is a potent neuromuscular paralyzing agent used in various disorders including cervical dystonia. Two preparations of botulinum toxin are now commercially available ( Dysport and Botox), but much controversy remains about their respective potencies. The aim of the study was to compare the efficacy of Botox with two different ratios of Dysport. A double blind, randomised, three period cross over study involving 54 patients with cervical dystonia was performed. The patients received the following treatments in a randomised order: Botox at the usually effective dose, Dysport at a dose of 1:3 (conversion factor of 3 between Botox and Dysport units-that is, one Botox unit=three Dysport units) and at a dose of 1:4 (conversion factor of four). The improvement of the Tsui (primary outcome criteria) and of the TWSTRS pain scales between baseline and a control visit 1 month after each of the three injections, as well as the incidence of adverse events, were assessed. Comparison of the Tsui scores and of the TWSTRS pain scores showed a better effect on impairment and pain with Dysport 1:3 (p=0.02 and 0.04, respectively) and 1:4 (p=0.01 and 0.02, respectively) than with Botox. The number of adverse events was higher with both Dysport treatments. The most frequent adverse event was dysphagia, found in 3%, 15.6%, and 17.3% (Botox, Dysport 1:3 and 1:4, respectively) of the patients. No adverse event required withdrawal of therapy or specific management. Dysport 1:3 (and Dysport 1:4 to a greater extent) is more efficient than Botox for both impairment and pain in cervical dystonia although with a somewhat higher incidence of minor adverse effects. This strongly suggests that the most appropriate conversion factor between Botox and Dysport units is less than 3 in cervical dystonia.Journal of Neurology Neurosurgery & Psychiatry 05/2002; 72(4):459-62. · 5.58 Impact Factor
Journal of the American Academy of Dermatology 02/2010; 62(2):346-7. DOI:10.1016/j.jaad.2008.12.028 · 5.00 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: Botulinum toxin (BTX) is an effective treatment for primary axillary hyperhidrosis. In this study we used two toxins not bioequivalent: BOTOX (Allergan, Inc.) and Dysport (Beaufour Ipsen Biotech). The objective was to compare the efficacy, safety, and tolerability of BOTOX and Dysport in the treatment of primary axillary hyperhidrosis using a conversion factor of 1:3, respectively. In a double-blind, randomized prospective study, 10 patients with primary axillary hyperhidrosis and sweat production exceeding 50 mg/minute received 50 U of BOTOX in one axilla and 150 U of Dysport in the other. We performed Minor's test and gravimetry at 0 days, at 15 days, and monthly for 1 year. No significant difference was observed in the sweating quantity at baseline. After 1 month all patients had achieved success for both axillae. The sweat rate was reduced by a mean of 97.7% for BOTOX and 99.4% for Dysport, without statistical difference. The duration of benefits was similar between both toxins, with a mean of 260 days for BOTOX and 290 days for Dysport, without statistical difference. The longest symptom-free interval was 12 months (5 patients, 55.6%). BOTOX and Dysport presented similar levels of safety and efficacy in the treatment of primary axillary hyperhidrosis when a conversion factor of 1:3 was used.Dermatologic Surgery 02/2007; 33(1 Spec No.):S44-50. DOI:10.1111/j.1524-4725.2006.32331.x · 1.56 Impact Factor